Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab + Chemo in Ovarian Cancer
NCT00718523Phase 2Terminated
- Sponsor
- Translational Research In Oncology
- Start
- Jan 2009
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of ganitumab in Epithelial Ovarian Cancer (EOC) (2 arms), sponsored by Translational Research In Oncology. Primary endpoint: Progression Free Survival at 3 years. Started Jan 2009; status: terminated.
02
Drugs
ganitumab
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT00718523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718523.